A scalable solution for isolating human multipotent clinical-grade neural stem cells from ES precursors. by Bohaciakova, Dasa et al.
UC San Diego
UC San Diego Previously Published Works
Title



















eScholarship.org Powered by the California Digital Library
University of California
Bohaciakova et al. Stem Cell Research & Therapy           (2019) 10:83 
https://doi.org/10.1186/s13287-019-1163-7METHOD Open AccessA scalable solution for isolating human
multipotent clinical-grade neural stem cells
from ES precursors
Dasa Bohaciakova1,7†, Marian Hruska-Plochan1†, Rachel Tsunemoto2,3†, Wesley D. Gifford2†, Shawn P. Driscoll2†,
Thomas D. Glenn2†, Stephanie Wu1, Silvia Marsala1, Michael Navarro1, Takahiro Tadokoro1, Stefan Juhas4,
Jana Juhasova4, Oleksandr Platoshyn1, David Piper5, Vickie Sheckler6, Dara Ditsworth3, Samuel L. Pfaff2* and
Martin Marsala1,8*Abstract
Background: A well-characterized method has not yet been established to reproducibly, efficiently, and safely
isolate large numbers of clinical-grade multipotent human neural stem cells (hNSCs) from embryonic stem cells
(hESCs). Consequently, the transplantation of neurogenic/gliogenic precursors into the CNS for the purpose of cell
replacement or neuroprotection in humans with injury or disease has not achieved widespread testing and
implementation.
Methods: Here, we establish an approach for the in vitro isolation of a highly expandable population of hNSCs
using the manual selection of neural precursors based on their colony morphology (CoMo-NSC). The purity and
NSC properties of established and extensively expanded CoMo-NSC were validated by expression of NSC markers
(flow cytometry, mRNA sequencing), lack of pluripotent markers and by their tumorigenic/differentiation profile
after in vivo spinal grafting in three different animal models, including (i) immunodeficient rats, (ii)
immunosuppressed ALS rats (SOD1G93A), or (iii) spinally injured immunosuppressed minipigs.
Results: In vitro analysis of established CoMo-NSCs showed a consistent expression of NSC markers (Sox1, Sox2,
Nestin, CD24) with lack of pluripotent markers (Nanog) and stable karyotype for more than 15 passages. Gene
profiling and histology revealed that spinally grafted CoMo-NSCs differentiate into neurons, astrocytes, and
oligodendrocytes over a 2–6-month period in vivo without forming neoplastic derivatives or abnormal structures.
Moreover, transplanted CoMo-NSCs formed neurons with synaptic contacts and glia in a variety of host
environments including immunodeficient rats, immunosuppressed ALS rats (SOD1G93A), or spinally injured
minipigs, indicating these cells have favorable safety and differentiation characteristics.
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Conclusions: These data demonstrate that manually selected CoMo-NSCs represent a safe and expandable NSC
population which can effectively be used in prospective human clinical cell replacement trials for the treatment of
a variety of neurodegenerative disorders, including ALS, stroke, spinal traumatic, or spinal ischemic injury.
Keywords: Human embryonic stem cell (hESC), Neural stem cell (NSC), Spinal cord, Amyotrophic lateral sclerosis
(ALS), Spinal traumatic injury, Bioinformatic tools to study xenografts,Background
Neurodegenerative diseases and traumatic CNS injuries
inflict untold morbidity, mortality, and economic burden
in the world [1–3]. One of the strategies considered for
treating neurological dysfunction is the use of neural
stem cell (NSC) transplantation to replace damaged cells
and/or repopulate the tissue with cells that modulate the
disease through neuroprotection [4, 5]. Although a het-
erochronic environment, previous animal experiments
have found that the transplantation of developmentally
immature neural stem cells (NSCs) into the mature CNS
leads to cell expansion, migration, maturation, and func-
tional integration of neurons, astrocytes, and oligoden-
drocytes into the host tissue [6–10].
Several established human NSC lines are being consid-
ered or are employed in ongoing human clinical trials
for the treatment of neurodegenerative disorders, includ-
ing spinal traumatic injury [11–13], ALS [14, 15], Par-
kinson’s disease [16–18], and stroke [19–21]. Based on
their origin, NSCs can be considered in two principal
categories: cells derived from immature fetal tissue that
contains undifferentiated lineage-committed neural or
glial precursors and NSCs derived in vitro from pluripo-
tent precursors such as embryonic stem (ES) or induced
pluripotent stem (iPS) cells. NSCs generated from fetal
tissue or pluripotent cell lines have specific advantages
and disadvantages with respect to the availability, ex-
pandability, and safety-tumorigenicity profile required
for clinical use.
Because human fetal neural tissue-derived NSCs
(FT-hNSCs) are developmentally committed to produ-
cing neurons, astrocytes, and oligodendrocytes, they
have limited capacity for tumor and teratoma formation.
However, there are ethical concerns and an increased
risk from the inherent variability that occurs with separ-
ate isolations of FT-NSCs from different embryos. By
contrast, human embryonic- and induced pluripotent
stem cells have an enormous capacity for expansion. In
addition, there are well defined in vitro methods for trig-
gering NSC differentiation from ES and iPS cells [22–
32]. The use of pluripotent cells as a starting source for
isolating NSCs, however, carries a risk of ES contamin-
ation and therefore is a serious safety concern because
of the potential for tumor or teratoma formation in cell
graft recipients.To isolate hNSCs from hESCs, previous studies have
employed stringent fluorescence-activated cell sorting
(FACS) or microwell adhesion schemes based on the
unique cell surface profile of hNSCs (CD184+, CD24+,
CD44− and CD271−) [29]. Although FACS purification
has proven to be a reliable method for isolating safe
hESC-derived hNSCs in animal research studies, the
cost of GMP-grade antibodies combined with the limited
availability of dedicated clinical FACS instrumentation
and expertise represent significant impediments for
widespread adoption of hESC- and iPSC-derived hNSCs
in clinical applications.
Here, we sought to identify a method for producing a
reliable, uniform, and safe population of clinical grade
hNSCs that was not reliant upon FACS or repeated fetal
tissue derivations. We opted to use hESCs as our source
material for producing hNSCs because of the scalability of
ES cultures and potential for banking large stocks of
well-characterized hESC and NSC lines. During neural
differentiation, hESCs undergo morphogenetic events
characterized by the formation of radially organized col-
umnar epithelial cells termed neural rosettes [24, 33].
These structures comprise cells expressing early neuroec-
todermal markers Pax6 and Sox1 and are capable of dif-
ferentiating into specific neuronal and glial cell types in
response to developmental cues [33, 34]. We found that a
stepwise selection process to isolate neural rosettes based
on their unique morphology followed by manual picking
of the emergent NSC clones was a reliable technique for
hNSC isolation. To distinguish the hNSCs purified based
on colony morphology from hNSC isolated using other
methods, we termed them CoMo-NSCs.
Gene profiling and immunocytochemistry revealed
that CoMo-NSCs lacked expression of pluripotent
markers such as Nanog and expressed NSC markers
Nestin, Sox1, Sox2, and CD24 through > 35 passages
while maintaining a stable karyotype. To test the safety
and potential applicability of CoMo-NSCs in vivo, we
engrafted these cells into the spinal cord of several types
of animal models: (i) naïve immunodeficient rats, (ii)
pre-symptomatic ALS (SOD1G93A)-immunosuppressed
rats, and (iii) adult immunosuppressed minipigs with
chronic spinal traumatic injury. Histochemistry and
comprehensive gene profiling of the engrafted cells using
species-specific bioinformatic filtering revealed that
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trocytes, and oligodendrocytes without forming terato-
mas, neoplastic derivatives, or abnormal structures. Our
findings indicate that CoMo-NSCs develop normally
even in the context of surrounding neurodegeneration
and inflammation initiated by a genetic mutation (ALS;
SOD1 mutation) or spinal traumatic injury. Thus,
CoMo-NSCs hold promise as a large-scale clinically rele-
vant source of neural and glial precursors.
Methods
Cell culture and differentiation
Experiments were performed on three cGMP-grade cell
lines of undifferentiated hESCs (H9, UCSF4, and
ESI-017). hESCs were grown on gelatin-coated dishes in
the presence of mouse embryonic fibroblasts (MEFs;
density 24,000 cells/cm2). Culture media was changed
every day and cells passaged every 5–7 days.
Differentiation of hESCs to NSCs was performed as de-
scribed in the “Results” section entitled “Differentiation
and isolation of NSCs.” Established NSCs were expanded
on a cell culture dish coated with poly-L-ornithine (Sig-
ma-Aldrich) and laminin (Thermo Fisher Scientific) (P/L)
and enzymatically passaged using Accutase (Stemcell
Technologies) at the seeding density of 25,000 cells/cm2.
All media compositions and dilutions are listed in Add-
itional file 1: Table S1.
All karyotype analyses (G-banding) were performed by
Cell Line Genetics LLC (Madison, WI) from live cell
cultures.
Flow cytometry and fluorescence-activated cell sorting
FACS of NSCs was performed according to the protocol
described by Yuan et al. [29] at the Human Embryonic
Stem Cell Core Facility at Sanford Consortium for Re-
generative Medicine (2880 Torrey Pines Scenic Dr.,
92037, La Jolla, CA) using BD FACS ARIA II SORP cell
sorter (BD Biosciences, Franklin Lakes, NJ, USA). After
sorting of CD184+/CD271−/CD44−/CD24+ NSCs, cells
were plated on P/L-coated cell culture dishes in the
density 25,000/cm2.
Expression of extracellular and intracellular markers
was determined using flow cytometry on fixed cell sam-
ples using BD LSRFortessa™ (BD Biosciences, USA). All
buffer compositions are listed in Additional file 1: Table
S1. All antibodies and corresponding isotype controls
are listed in Additional file 2: Table S2).
In vitro terminal neuronal and astrocyte differentiation of
NSCs and indirect immunofluorescence
NSCs were plated onto glass chamber slides and induced
to terminally differentiate using media supplemented
with BDNF, GDNF, and cAMP (neuronal differentiation)
or 10% FBS (glial differentiation) for 3–6 weeks. Detailedcomposition of media can be found in Additional file 1:
Table S1. After induction cells were stained with neur-
onal and glial markers and images captured and ana-
lyzed with a Fluoview FV1000 confocal microscope
(Olympus, Center Valley, PA, USA). All primary and
secondary antibodies are listed in Additional file 2: Table
S2.
Electrophysiology
Whole-cell patch recordings were performed on
CoMo-NSCs that were infected with HIV1-Synapsin
(SYN)-green fluorescent protein (GFP) lentivirus (ob-
tained from UCSD Vector Core, Dr. Atsushi Miyano-
hara, Department of Anesthesiology, UCSD) and
differentiated for 5 weeks prior to recording. The record-
ing micropipettes (tip resistance 4–6MΩ) were filled
with internal solution: 135 mMK-gluconate, 4 mM
MgCl2, 10 mM HEPES, 10 mM EGTA, 4 mMMg-ATP,
and 0.2 mM Na-GTP (pH 7.4). Recordings were made
using a MultiClamp 700B amplifier and Digidata 1440A
interface (Molecular Devices). Signals were filtered at 10
kHz and sampled at 10 kHz. The whole-cell capacitance
was fully compensated. The bath was constantly per-
fused with fresh HEPES-buffered saline: 140 mM NaCl,
5 mM KCl, 10 mM HEPES, 1 mM EGTA, 3 mM MgCl2,
and 10 mM glucose (pH 7.4). For current-clamp record-
ings, cells were clamped at a range of − 60 to − 80 mV.
For voltage-clamp recordings, cells were clamped at −
60mV. Cells were visualized using an OLYMPUS
BX51W1 fixed-stage upright microscope. All recordings
were performed at room temperature.
Immuno-electron microscopy
Transverse spinal cord sections (50-μm-thick) were
prepared from lumbar spinal cords of immunodefi-
cient rats at 6 months after CoMo-NSCs grafting. Sec-
tions were cut on a vibratome and cryoprotected with
glycerol–dimethylsulfoxide mixture. After cryoprotec-
tion, the sections were frozen and thawed four times
and treated with 1% sodium borohydride. To reduce
nonspecific binding, the sections were treated with
0.3% H2O2–10% methanol in TBS (100 mM Tris-HCl
and 150 mM NaCl, pH 7.6) and 3% NGS–1% bovine
serum albumin in TBS. Sections were reacted over-
night with mouse anti-human-specific synaptophysin
(1:1000; Chemicon). Bound antibody was detected
using biotinylated donkey anti-mouse IgG (1:500; GE
Healthcare, Little Chalfont, UK), the ABC Elite kit
(Vector Laboratories, Burlingame, CA), and diamino-
benzidine (DAB) as the chromogen. After DAB detec-
tion, some sections were processed by an additional
antibody labeling cycle using the same method and
antibody as above. This staining strategy enhanced
the signal-to-background ratio while the background
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were post-fixed in buffered 2% OsO4, rinsed and
stained in 1% uranyl acetate, and then dehydrated
and embedded in Epon. Ultrathin sections were con-
trasted with uranyl acetate and analyzed under a Zeiss
EM-10 electron microscope operated at 60–80 kV.
Digital electron microscopic images were processed
by Adobe Photoshop CS2 (Adobe Systems).
In vivo cell grafting, surgical procedure, and experimental
groups
Experimental groups and “n” numbers are summarized
in Additional file 3: Table S3.
First, the adult athymic rats (Crl:NIH-Foxn1rnu;
Charles River) and 40-day-old immunocompetent
transgenic ALS rats (SOD1G93A) were used for spinal
NSC grafting in the rodent component of this
in vivo grafting study. After cell grafting, ALS rats
were continuously immunosuppressed using a com-
bined immunosuppression protocol composed of
subcutaneously implanted sustained-release tacroli-
mus pellet (3 mg/kg/day, continuous release) and
mycophenolate mofetil (10 mg/kg/day; ip for 7 days)
as previously described [35, 36]. To graft NSCs
spinally, the previously described technique was used
[36, 37]. Animals received 10–15 spinal NSC injec-
tions (0.5 μl each) distributed bilaterally between L2–
L6 spinal segments (15,000 viable cells per injection).
Cell-grafted athymic rats were sacrificed and imme-
diately transcardially perfusion-fixed with 4% para-
formaldehyde at 3 weeks, 6–8 weeks, or 6 months.
SOD1G93A rats survived between 56 and 70 days after
grafting which corresponded with the stage of early
disease onset. On the day of sacrifice, all animals
were transcardially perfusion-fixed with 4%
paraformaldehyde.
Second, adult minipigs with previous spinal trau-
matic injury were employed for spinal cell grafting.
Adult female Gottingen-Minnesota minipigs (n = 3)
were anesthetized and the Th9 spinal segment ex-
posed after partial dorsal laminectomy of the L2–3
vertebra as previously described [38]. The exposed L3
segment was compressed (1 cm/s) with an aluminum
rod (5 mm in diameter) using a computer-controlled
apparatus. Compression pressure cut-off was set at
2.5 kg. After trauma, animals survived for 2.5 months
before spinal NSC grafting. At 2.5 months after induc-
tion of spinal injury, animals were re-anesthetized and
a chronic jugular catheter (8G) placed into the right
jugular vein. The site of previous spinal cord injury
was then exposed, and the dura was cut open. Ani-
mals then received a total of 20 injections of
CoMo-NSCs (10 μl/injection; 20,000–30,000 cells/μl;
flow rate = 2 μl/min) targeted above and below theinjury epicenter. From the day of cell grafting, ani-
mals were continuously immunosuppressed by tacroli-
mus (0.025 mg/kg/day) for 3 months by using an
externally mounted 11-day infusion pump (Baxter
Infusor, USA) [39]. After survival, animals were perfu-
sion fixed with 4% paraformaldehyde for immuno-
fluorescence analysis of the spinal cord.
Perfusion fixation, indirect immunofluorescence staining
of spinal cord sections, and quantitative analysis of
grafted cell neuronal and glial differentiation
At the end of survival, rats were anesthetized with 2 mg
pentobarbital and 0.25 mg phenytoin (0.5 mL of
Beuthanasia-D, Intervet/Schering-Plough Animal Health
Corp., Union, NJ, USA) and transcardially perfused with
200 ml of heparinized saline followed by 250 ml of 4%
paraformaldehyde (PFA) in PBS. Spinal cord sections
were then prepared and stained with a combination of
human-specific and non-specific antibodies (Add-
itional file 2: Table S2) as previously described [35].
For quantitative analysis, sections taken from immu-
nodeficient rats at 3 weeks, 8 weeks, and 6 months after
NSC grafting were used (minimum of n = 4 for each
time point). Three sections taken from each animal with
identified grafts were used for staining and quantifica-
tion. Sections were stained with hNUMA antibody in
combination with neuronal and glial markers including
DCX, hNSE, NeuN, hGFAP, and vimentin. The total
number of double-stained grafted cells was then counted
and expressed as % of the total hNUMA-stained cell
population.
RNA sequencing and data analysis
RNA was isolated from in vitro cultured NSCs or
NSCs-grafted spinal cord specimens using the miRvana
miRNA isolation kit (Ambion AM1560). The protocol for
total RNA collection was used. Median RNA input was
740 ng (IQR 660–810 ng) and RIN scores were 9.5 ± 0.3 (as
determined by Beijing Genomics Institute). Paired-end 100
bp RNA sequencing libraries were prepared using the Tru-
Seq RNA Library Preparation Kit (v2) according to the
manufacturer’s instructions (Illumina). Briefly, RNA with
polyA+ tails was selected using oligo-dT beads. mRNA was
then fragmented and reverse-transcribed into cDNA.
cDNA was end-repaired, index adapter-ligated, and PCR
amplified. AMPure XP beads (Beckman Coulter) were used
to purify nucleic acids after each step. Samples were se-
quenced on an Illumina HiSEQ 2000 by the Beijing Gen-
omics Institute or on an Illumina NextSeq 500 at the Salk
Next Generation Sequencing Core.
TruSeq adapters were trimmed from reads. Only reads
> 50 bp were retained. The remaining reads were filtered,
selecting for reads with > 15 average base quality. Trim-
ming and filtering were performed with the BBMap
Bohaciakova et al. Stem Cell Research & Therapy           (2019) 10:83 Page 5 of 19(BBTools) package. For gene expression quantification,
we used Sailfish with Gencode’s v19 human annotation
for hg19. Sailfish was run with default settings.
Because human and rat mRNA transcripts might
cross-contaminate in an unpredictable manner, we
tested our bioinformatics pipeline with a simulated
read sorting experiment. mRNA sequencing reads
from pre-transplanted NSC samples were artificially
mixed with mRNA reads from a control athymic rat.
The resulting mixture of mRNA reads was then
processed in our pipeline to determine the rate of
false positives in our species sorting method. 0.3% of
rat mRNA reads falsely sorted to human (with 1.4%
ambiguous), while 0.04% of human reads falsely
sorted to rat (with 2.3% ambiguous). In this analysis,
we mixed human and rat mRNA reads at differing
proportions, up to 50% of each, and noticed that the
false sorting rate remained stable at all ratios of
mixing. Approximately 78% of the rat reads that
falsely sorted to the human genome mapped to
genes, while the remaining 22% mapped to non-exon
regions of the human genome.
Differential expression testing was performed by using
DESeq2, edgeR, and voom-limma in R in GLM run
modes. Genes with expression levels lower than 1 count
per million in all groups were discarded from final test-
ing. p values were corrected for multiple comparisons
within the model with the Sidak method, and genes were
adjusted to control FDR with the Benjamini–Hochberg
method. Final p values are computed from the three dif-
ferential expression pipelines by taking the median
Sidak/Benjamini–Hochberg corrected p value at each
gene (i.e., significant in two of the three pipelines).
Genes were considered significant at p < 0.05.
In order to compare gene expression between pre
and post-transplantation NSCs, we first compensated
for the expected error rate introduced by rat mRNA
reads falsely sorted as human in the mixed-species
sample of post-transplantation NSCs. To compensate
for this, when quantifying gene expression from
pre-transplantation NSCs, we first artificially mixed
the NSCs into a background of nude rat mRNA reads
at the same percentage as occurred in the actual graft
tissue. We then sorted the human mRNA reads back
out via the bioinformatics pipeline described. This re-
sulted in the pre and post-transplantation NSCs hav-
ing a similar percentage of false positive rat mRNA
reads contaminating the sample (approximately 0.3%).
Principal component analysis was performed using a
subset of genes (minimum 5 TPM in 50% of the sam-
ples). We used the “variance stabilization” transform
provided by the DESeq package in R on normalized
estimated counts from the Sailfish quantification pipe-
line prior to the analysis.Results
Differentiation and isolation of NSCs
Colonies of pluripotent hESC lines H9 (46, XX), UCSF4
(46, XX), and ESI-017 (46, XX) [40] with well-defined
edges in brightfield microscopy were manually dissoci-
ated and induced to form embryoid bodies (EBs) by
transferring to non-adherent dishes (Fig. 1a; Add-
itional file 4A, B). After 4–6 days, EBs were transferred
onto culture dishes coated with poly-L-ornithine and
laminin (P/L) and allowed to adhere for 48 h in NSC
media with 20 ng/ml of bFGF. Over a period of 4–12
days in the adherent dishes, radially organized
columnar-shaped cells formed rosette structures which
were readily identified in areas occupied by
attached-induced EBs (Additional file 4C).
Rosettes were manually dissected and re-plated
into adherent dishes, which led to the generation of
secondary rosettes (R1) (Additional file 4D). Com-
pared to the primary rosettes, R1 rosettes were
smaller and remained radially organized, which dis-
tinguished them from the sparse heterogeneous epi-
thelial cell clusters. On days 2–4, R1 rosettes were
again manually picked, dissociated, and transferred
to P/L-coated dishes. From these cells, islands of R2
radially organized rosettes emerged with fewer het-
erogeneous neuroectodermal cells apparent (Add-
itional file 4E, F). The R2 rosette population was
then used for isolating NSCs following two different
isolation protocols. First, as a control, we utilized a
previously established FAC-sorting isolation protocol
[29]. We dissociated R2 rosettes and purified NSCs
using NSC-specific surface markers, CD24+/CD184+/
CD44−/CD271− NSCs. These FAC-sorted NSCs
(FACS-NSCs) were used as a control NSC popula-
tion for comparison to our newly established NSC
purification method, which did not employ FACS.
The second purification method entailed re-plating
the R2 rosettes and manually isolating the columnar
epithelial cell colonies (NSCs-like cells) that ap-
peared outside of each rosette in separate wells of
24-well plates (Additional file 4G-L). Wells that con-
tained NSCs with a homogenous morphology, good
attachment, and survival were expanded as colony
morphology NSCs (CoMo-NSCs).
We noted that hESC line H9 and ESI-017 gave rise to
numerous FACS-NSCs and CoMo-NSCs, whereas UCSF4
was less efficient (data not shown). This is consistent with
previously noted variability in differentiation among differ-
ent human ES lines [41]. Thus, selection of an appropriate
hESC, and possibly iPSC, lines will likely help to improve
the efficiency of NSC production from pluripotent stem
cells for clinical applications regardless of the purification
method. Variable differentiation characteristics are also
likely to extend to different isolates of fetal precursor cells.
Fig. 1 Strategy for generation, expansion, and characterization of human embryonic stem cell-derived neural stem cells. a Schematic diagram
depicting the experimental design of in vitro ES-NSCs generation and in vitro and in vivo post-grafting characterization. b, c Morphology of NSCs
derived by FACS Sorting (FACS-NSCs) and clonal morphology manual selection (CoMo-NSCs) at passage 10 and 15. d, e Expression of NSC-
specific and ESC-specific markers determined by flow cytometry at passages less than 15 (d) and greater than 15 (e). Data are represented as
mean ± SEM. f Differential gene expression plot showing the log-fold change and average transcripts per million (TPM) of each gene when
comparing CoMo-NSCs and FACS-NSCs. Gray dots represent genes that are not significantly different between the two groups; the absence of
black dots seen in the plot indicate that there were no genes that were significantly different between the two groups. g Heat map of log2(TPM
+1) values of genes that distinguish ESCs from FACS-NSCs across ESC, FACS-NSC, and CoMo-NSC samples. The selection of genes is described in
the methods (scale bars: b, c 50 μm)
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NSC isolates
To determine whether FACS- and CoMo-NSCs had
similar growth characteristics, we isolated and ex-
panded H9 and ESI-017-derived-NSCs in vitro using
both purification methods and monitored their
growth and differentiation characteristics. Previous re-
ports have found that some isolates of NSCs are
prone to spontaneous differentiation upon prolonged
propagation [24, 42]. We found that CoMo-NSCs
maintained growth rates similar to FACS-NSCs and
retained their characteristic columnar morphology
with refractive edges under brightfield microscopy for
10 and 15 passages (Fig. 1b, c). To determine the dif-
ferentiation stage of proliferating NSCs, we used
FACS to quantify the expression of a battery of celltype markers. We analyzed the expression of a pluri-
potency marker expressed by hES cells (Nanog),
NSC-specific markers (Pax6, Sox1, Sox2, Nestin,
CD24) a marker of neural crest cells (p75), and a
marker of astrocytes (CD44), (Fig. 1d, e). We detected
no labeling with the pluripotency marker Nanog
(Fig. 1d, e) and very low levels of p75+ (CD271)
neural crest cells and GFAP+ astrocytes (not shown).
In contrast, both FACS- and CoMo-NSCs were highly
enriched with cells expressing NSC markers. At pas-
sages < 15, CoMo-NSCs were labeled by Nestin
(98.27% ± 0.53), Sox1 (88.49% ± 6.98), Sox2 (91.8% ±
2.5), and CD24 (99.1% ± 0.68). We noted some vari-
ability in Pax6 (57.26% ± 17.58) and CD44 (17.6% ±
10.08) labeling among CoMo-NSCs, but this was
similar to the apparent heterogeneity of these markers
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marker expression remained similar in the NSC cul-
tures as passage number increased (Fig. 1d, e).
We next compared the gene expression between pluri-
potent hESC, multipotent FACS-NSCs, and
CoMo-NSCs using next-generation mRNA sequencing.
As expected, a large change in the mRNA reads between
pluripotent versus established NSCs (both FACS-NSCs
and CoMo-NSCs) was detected (Fig. 1g). In contrast, a
comparison of FACS-NSCs to CoMo-NSCs grown under
proliferating conditions revealed that both cultures dis-
play a nearly identical gene expression profile (Fig. 1f, g).
Our findings suggest that manual selection of NSC col-
onies that display a radial columnar morphology with re-
fractive cell edges is effective for enriching NSCs (i.e.,
CoMo-NSCs) that have a genetic profile similar to NSCs
isolated by FACS purification. Because CoMo-NSCs ap-
pear to provide a distinct advantage for future GMP pro-
duction and clinical applications over FACS-NSCs by
circumventing the need to generate GMP-grade anti-
bodies and the use of dedicated clinically approved sort-
ing equipment, we further explored the properties of
CoMo-NSCs.
CoMo-NSCs efficiently self-renew and generate neurons
and glia in vitro
Based on the observation that cultured CoMo-NSCs
proliferate, retain a homogenous morphology, and ex-
press NSC markers at higher passages (Fig. 1c–e), we
further examined the in vitro characteristics ofFig. 2 In vitro proliferating clonal morphology-derived NSCs (CoMo-NSCs)
of immature NSCs. a, b Characteristic stable morphology of CoMo-NSCs in
(Sox1, Sox2, Nestin, CD24, Pax6, and CD44) evaluated by flow cytometry at
Expression of NSC-specific markers (Sox2, Nestin, Plzf, Dach-1, N-cadherin) a
determined by indirect immunofluorescence (scale bars: a, b 25 μm; d–f 10CoMo-NSCs from passages < 12, 13–20, and 21–36. The
undifferentiated columnar morphology of CoMo-NSCs
was observed for > 40 passages. Cells typically organized
as clusters at both low and high density with an average
doubling time of 20.96 h ± 1.51 and retained a normal
karyotype (Fig. 2a, b; Additional file 5A, B). Cells
expressed NSC-specific proteins Nestin, Sox2, Plzf,
Dach-1, and N-cadherin at passage 17 (Fig. 2d–f ). Tight
junction protein ZO-1 was detected asymmetrically in
the central parts of NSC clusters, confirming the polar-
ized epithelial organization (Fig. 2e). Typical NSC
markers Sox2, Sox1, Nestin, and CD24 were stably and
highly expressed by CoMo-NSCs from passage < 10 to >
20, as detected using flow cytometry (Fig. 2c). As ex-
pected, astrocytic marker CD44 remained low, and Pax6
was detected at moderate levels (Fig. 2c).
A hallmark of NSCs is their ability to produce neur-
onal and glial (astrocytic, oligodendrocytic) progeny. We
treated CoMo-NSCs with astrocyte-differentiation media
(10% FBS; see the “Methods” section). Over 3–6 weeks
after induction, proliferation slowed and cells exhibited a
larger and flatter morphology (Fig. 3a, b). Staining with
CD44 and human-specific GFAP antibodies detected
high numbers of CD44+ cells, but very few or no GFAP
+ cells in the CoMo-NSC culture at 3–6 weeks (Fig. 3c,
d, data not shown). This staining pattern was similar to
human fetal astrocyte cultures (Fig. 3e, f ).
Flow cytometry confirmed that > 85% of differentiated
astrocytes expressed cell surface-bound CD44, while less
than 1% were GFAP+ (Fig. 3g). Next, CoMo-NSCs wereshow consistent morphology and expression of markers characteristic
low (a) and high (b) density. c Expression of selected NSC markers
different passages. Data are represented as mean ± SEM. d–f
nd tight junction protein ZO-1 in undifferentiated CoMo-NSCs as
μm)
Fig. 3 CoMo-NSCs generate astrocytes and functional neurons upon in vitro differentiation. a, b Changing morphology of differentiating CoMo-
NSCs towards large flat cell type after 40 days treatment with astrocyte-inducting media. c–f Expression of human-specific GFAP (hGFAP) and
CD44 in CoMo-NSCs-derived astrocytes and human fetal brain-derived astrocytes. A comparable expression pattern for both markers can be seen.
g Representative flow cytometry plots from fixed/permeabilized cells at day 21 of astrocyte differentiation. CoMo-NSC-derived astrocytes were
nearly all CD44+, with a fraction expressing GFAP. Primary fetal astrocytes (ScienCell) were used as a positive control, compared to CoMo-NSCs as
a negative control. All cells lacked signal when analyzed in the absence of antibodies (data not shown). h Expression of synapsin promoter-driven
GFP and appearance of neuronal morphology in CoMo-NSC-derived neurons at 6 weeks after induction using BDNF, GDNF, and cAMP. i–l
Expression of neuronal markers (DCX, MAP2, human-specific axonal neurofilament HO14 and NeuN) in CoMo-NSC-derived neurons at 6 weeks
after induction. m–p Patch-clamp recording in Syn-GFP neurons in vitro: voltage-clamp recording in Syn-GFP + neurons with fast inward (Na+)
and persistent outward (K+) currents in depolarized membrane potentials (characteristic of neuronal cells) can be seen (o). In current-clamp
recording (membrane potential − 65 mV), action potentials are triggered by depolarizing current pulses (p) (scale bars: a, b 100 μm; c, e 10 μm; h
200 μm; i–k 50 μm; l 25 μm)
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BDNF/GDNF/cAMP (see the “Methods” section). After
induction, proliferation slowed and the morphologychanged towards a neuronal phenotype with an exten-
sive axo-dendritic arborization (Fig. 3h). These changes
were accompanied with an upregulation of neuronal
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filament (HO14) (Fig. 3i, j). Very few GFAP+ astrocytes
and Olig2+ oligodendrocytes were detected (not shown).
To confirm that bona fide functional neurons were
generated in vitro from CoMo-NSCs, we performed
patch-clamp recordings on cells from an NSC clone ex-
pressing Synapsin-GFP as previously described [43]. GFP
was readily detected in DCX, NeuN, and HO14+ neu-
rons (Fig. 3k–n). Voltage clamp was used to record
membrane potentials from depolarized cells and fast in-
ward Na+ and persistent outward K+ currents character-
istic of neurons were detected (Fig. 3o). In
current-clamp mode, with cells at a resting membrane
potential of − 65 mV, action potentials were triggered by
depolarizing current pulses (Fig. 3p).
Transplanted CoMo-NSCs differentiate into glia and
neurons within the mature CNS
The signals that trigger neuroepithelial progenitor cell
differentiation in vivo are normally present during em-
bryonic development. Numerous studies with human
ESC or iPSC-derived NSCs have found that they can
safely differentiate into neurons, astrocytes, and oligo-
dendrocytes when transplanted into the mature CNS in
small and large animal models [10, 43, 44]. This suggests
that this environment is permissive for the maturation
of multipotential cells. To evaluate whether CoMo-NSCs
can likewise differentiate into neurons and glia when
engrafted into the mature CNS, while not forming aber-
rant pathological structure such as cysts, teratoma, or
tumors, we grafted CoMo-NSCs into the lumbar spinal
cord gray matter of athymic-immunodeficient rats (see
Additional file 3: Table S3 for experimental groups;
Fig. 4a). The fate of the human CoMo-NSCs was ana-
lyzed at 3 weeks, 6–8 weeks, and 6 months. All
cell-grafted animals showed normal motor and sensory
neurological functions with no overt signs of motor
weakness, muscle spasticity or allodynia for the duration
of the study (data not shown).
A histological analysis of transverse lumbar sections
taken from cell-grafted segments and stained with H&E
and human-specific neuron-specific enolase (hNSE)
showed the engrafted cells had become incorporated into
the host tissue. We did not observe hyper-cellularity due
to graft over-proliferation, which can cause tissue expan-
sion or the appearance of tumors such as teratomas and
glioblastomas (Fig. 4b–d). At 3 weeks after cell grafting,
immunofluorescence staining of spinal cord sections
showed well-delineated hNUMA-immunoreactive grafts
(Fig. 4f). To probe for the degree of neuronal and/or glial
differentiation, sections were stained with early glial
(Vimentin) and neuronal (DCX) markers. Numerous
Vimentin+ cells were identified within individual grafts, as
well as, migrating into the surrounding host tissuetowards the host ChAT+ α-motor neurons (Fig. 4f). Simi-
larly, staining with DCX (early post-mitotic neuronal
marker) showed an intense DCX immunoreactivity
throughout the graft with a well-developed DCX+
axo-dendritic network (Fig. 4g).
At 6–8 weeks after transplantation, in addition to an
intense DCX immunoreactivity seen in hNUMA+ neu-
rons (Fig. 4h), a high density of human axons (HO14)
were observed throughout the graft region (Fig. 4i). At
both 3 weeks and 6–8 weeks, minimal hGFAP immuno-
reactivity was detected (not shown). At 6 months
post-grafting, the expression of markers which are typ-
ical of mature neural grafts (such as hNSE) was seen in
the whole graft (Fig. 4j). Individual hNSE+ neurons
which migrated out of the graft were also identified
(Fig. 4j; white arrow). Staining with human-specific
GFAP (mature astrocyte marker) and CC1 (oligodendro-
cyte marker) antibody at this later time point revealed a
high number of mature human astrocytes and oligoden-
drocytes (Fig. 4k, Additional file 6A-F). Co-staining with
hNUMA (human-specific nuclear marker) and Ki67 (cell
division marker) antibody detected only occasional
double stained cells (Additional file 6G). Quantitative
analysis of early and late neuronal markers (DCX, NeuN,
hNSE) and glial markers (Vimentin, hGFAP) in grafted
cells showed the initial expression of early neuronal
marker (DCX) and then progressive appearance of late
neuronal markers (NeuN, hNSE) and mature astrocyte
marker (hGFAP) at 2–6 months post-grafting (Fig. 4e).Transplanted CoMo-NSCs differentiate within a
neurodegenerative environment
A potential application for NSCs is the treatment of
neurodegenerative diseases. However, there are likely
important environmental differences within the nor-
mal CNS compared to the disease state. To study the
differentiation profile of CoMo-NSCs within a neuro-
degenerative environment, cells were grafted into
lumbar spinal cord gray matter in SODG93A trans-
genic rats, which develop an aggressive form of amyo-
trophic lateral sclerosis (ALS) with a mean survival
age of 100 days [45]. Animals were grafted at pre-
symptomatic age (40 days old) and spinal cord sec-
tions analyzed using immunofluorescence staining
between 56 and 70 days after grafting. Staining with
hNUMA antibody showed well-delineated human cell
grafts in the central gray matter (Fig. 4l). The grafts
contained a high density of DCX+ neurons and some
double DCX/NeuN-stained grafted neurons (Fig. 4l).
Staining with hNUMA and hGFAP antibody showed a
moderate density of human astrocytes in NUMA+
grafts adjacent to ChAT+ motor neurons undergoing
degeneration (Fig. 4m).
Fig. 4 (See legend on next page.)
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Fig. 4 Spinally grafted clonal-derived NSCs show a long-term engraftment, no tumor formation, and time-dependent expression of human-
specific markers characteristic of immature and mature neurons and glial cells. a Single suspension of NSCs was injected bilaterally into central
gray matter of lumbar spinal cord segments in immunodeficient or G93A ALS rat using glass capillary. b Grafted cells were identified by
expression of human-specific markers such as hNSE (green; white arrows). c, d H&E staining of lumbar spinal cord section at 6 months after NSCs
grafting show well engrafted cells (red dotted area) with no detectable tumor formation. e Quantitative analysis of neuronal and glial
differentiation at 3 weeks, 8 weeks, and 6 months after spinal NSC grafting in immunodeficient rats. Data are expressed as percent of double-
stained hNUMA/DCX, hNUMA/hNSE, hNUMA/NeuN, hNUMA/GFAP, and hNUMA/Vim relative to hNUMA+ cells. Data are presented as mean ± SD.
f, g At 3 weeks after grafting, a marker characteristic for proliferating immature glial precursors (Vimentin) and early post-mitotic neurons (DCX)
are seen in grafted hNUMA+ cells. Extensive axo-dendritic sprouting of DCX+ positive processes surrounding the host interneurons and α-
motoneurons can be seen (g). h, i At 6–8 weeks after NSCs transplantation, a more advanced cell migration and neuronal maturation were seen.
Numerous double hNUMA/DCX+ neurons residing outside of the graft core were identified in the gray matter (h). Similarly, extensive axonal
sprouting of HO14+ human axons was seen in the host gray matter (i). j, k At 6 months after NSCs grafting the appearance of mature neuronal
and glial markers was identified throughout the graft. A high intensity of human-specific NSE was seen in grafted areas with several hNSE+
neurons identified outside of the graft (j, white arrow). Staining with human-specific GFAP antibody showed a high density of GFAP+ network
with numerous hGFAP+ processes found in the ventral gray matter between α-motoneurons of the host (k). l, m Analysis of grafted NSCs at 56
days after grafting in G93A ALS rat lumbar spinal cord. A high density of double hNUMA/DCX-stained grafts was seen throughout the grafted
segments (l). Staining with hGFAP showed only relatively few hGFAP+ astrocytes and these were preferentially found at the borders of individual
hNUMA+ grafts (m) (scale bars: b, c 500 μm; f, g 100 μm; h, i 300 μm; j 300 μm; k 100 μm; l 300 μm; m 200 μm)
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contacts with host neurons
A key requirement to achieve a clinically relevant benefit
in neuron-replacement therapies is a functional,
synapse-coupled incorporation of grafted neurons into
the local neuronal circuitry.
To study the development of synaptic contacts be-
tween grafted CoMo-NSCs-derived neurons and host
neurons in more detail, sections were harvested at 6
months post-grafting in immunodeficient rats and
stained with a combination of human-specific synapto-
physin (hSYN), human-specific axonal neurofilament
(HO14) and neurotransmitter phenotype-specific anti-
bodies including VGAT (vesicular GABA transporter),
GAD65 (glutamate decarboxylase), and VGLUT1–3
(vesicular glutamate transporters). A separate set of sec-
tions were used for pre-embedding immunohistochemis-
try, stained with human-specific synaptophysin antibody
and then processed for electronoptical analysis of syn-
apse formation. Immunofluorescence staining with
hSYN, HO14, and ChAT antibodies showed a high dens-
ity of human axons and hSYN puncta in the vicinity of
host interneurons and ChAT+ α-motoneurons (Fig. 5a).
Similarly, using pre-embedding immunohistochemical
staining with hSYN showed numerous hSYN+ puncta in
the vicinity of large host neurons (Fig. 5b). Electronopti-
cal analysis of ultrathin sections previously stained with
hSYN showed identifiable synapses between hSYN+ ter-
minals and the host neurons with well-developed pre-
and post-synaptic densities (Fig. 5c; red boxed area).
Triple staining with VGAT/hSYN/NeuN antibodies re-
vealed a high density of double-stained VGAT/hSYN
puncta in the core of the graft as well as in surrounding
host tissue (Fig. 5d–i). Several VGAT/hSYN+ boutons
were identified on membranes of large NeuN+ neurons
of the host, suggesting the development of putativeinhibitory synaptic contacts (Fig. 5f; white arrows). Pre-
vious electronoptical studies have demonstrated that
spatial co-localization of VGAT+ terminals with
post-synaptically expressed Gephyrin corresponds with
the presence of glycinergic synapses in rat spinal cord
dorsal horn neurons [46]. We therefore triple-stained
sections with hSYN/Gephyrin and VGAT antibodies.
Numerous double hSYN/VGAT-stained terminals op-
posed to gephyrin immunoreactivities on neuronal
membranes of the host were identified (Fig. 5j–m;
white arrows). These data confirm the presence of
glycinergic synapses between grafted neurons and
neurons of the host. Quadruple staining with GAD65/
VGLUT1–3/hSYN/NeuN antibodies revealed fewer
hSYN/VGLUT1–3-stained terminals (Fig. 5n–p).
Quantitative analysis showed on average 37.4 ± 2.6%
of hSYN/VGAT+ terminals and 0.1 ± 0.03% of hSYN/
VGLUT1–3+ terminals.
Transcriptome analysis of transplanted CoMo-NSCs
Although immunostaining to detect markers of cell
types is informative, we sought to identify and develop a
more comprehensive method for analyzing the fate and
safety profile of engrafted cells. We reasoned that mRNA
sequencing could be performed on mixed-species grafts,
and that human transcripts could be separated from rat
transcripts through bioinformatics methods. To ap-
proach this problem, we developed a bioinformatics
pipeline (Fig. 6a). mRNA was extracted from
mixed-species graft tissue and was sequenced with an
Illumina sequencing platform (see the “Methods” sec-
tion). Every read that was generated in the sequencing
run was aligned to both the rat and human genome, and
alignment scores were generated based on base-pair
mismatches and insertions/deletions. Reads that did not
align to either genome with a threshold score of at least
Fig. 5 Spinally grafted clonal NSCs-derived neurons acquire preferential inhibitory neurotransmitter phenotype and develop synaptic contacts with host
neurons in the immunodeficient rat at 6months post-grafting. a A high density of human-specific synaptophysin puncta (hSYN) in areas occupied by
human axons (HO14) and residing in the vicinity of the host ChAT+ α-motoneurons can be seen. b, c Pre-embedding immunohistochemical staining with
hSYN antibody coupled with electron-optical analysis showed numerous hSYN+ puncta (b; semithin 1 μm section) and developed synaptic contacts
between hSYN+ terminals and host neurons with readily identifiable pre- and postsynaptic densities (c; red boxed area). d–i Triple staining with VGAT,
hSYN and NeuN antibody showed a high-density hSYN puncta through the graft as well as in surrounding host tissue. A high number of hSYN + puncta
co-expressed VGAT and were residing on the membranes of the host ChAT+ α-motoneurons (f; white arrows). j–m Triple staining with VGAT, hSYN, and
gephyrin (glycine receptor-associated protein) showed numerous double-stained hSYN/VGAT+ puncta in opposition to postsynaptically bound gephyrin+
profiles (j–l, m-white arrows). n–p Staining with GAD65, hSYN, NeuN, and VGLUT1–3 antibodies showed only occasional presence of VGLUT1–3+ terminals
in association with hSYN puncta (scale bars: a 30 μm; b 20 μm; c 350 nm; d 500 μm; e 50 μm; f 30 μm; g–i 10 μm; j 20 μm; m, p 5 μm)
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Most reads only aligned to one, but not both genomes,
and so species assignment was unambiguous. For am-
biguous cases in which a read sorted to both the human
and rat genomes, alignment scores between the two spe-
cies were compared in order to assign the species.
We first sequenced human ESI-017 hESCs and un-
differentiated CoMo-NSCs derived from this hESCline to establish baseline transcriptomes for these two
cell populations. As expected, the transcriptomes of
hES and CoMo-NSC cells differed significantly from
one another. hESCs expressed high levels of pluripo-
tency transcription factors including Oct4, Nanog,
Sox2, Klf4 and Myc; whereas CoMo-NSCs downregu-
lated Oct4, Nanog, Sox2, Klf4 and expressed high
levels of Pax6, Sox1, Dach1, Zbtb16 (Plzf ), Plagl1,
Fig. 6 RNA-Seq analysis of transplanted CoMo-NSCs in immunodeficient rats at 2 and 6months post-transplantation using bioinformatics-based
species splitting. a Generalized schematic of RNA-Seq analysis pipeline using bioinformatics-based species splitting. Following analyses were
conducted using the resulting human-specific transcripts only, reflecting expression profiles of the human CoMo-NSCs. b Principal components
analysis (PCA) of three populations: CoMo-NSCs pre-transplantation (black dots, n = 2), CoMo-NSCs 2 months post-transplantation (red dots, n = 3),
and CoMo-NSCs 6 months post-transplantation (blue dots, n = 3). The plot depicts principal components 1 (PC1) and 2 (PC2) with the percent of
variance for each component. c, d Differential gene expression plot comparing CoMo-NSCs 2 months post-transplantation to CoMo-NSCs pre-
transplantation (c) and 6months post-transplantation to 2 months transplantation (d) as depicted as log2 average gene expression levels versus
log2 fold change. Black dots represent genes that are significantly differentially expressed (p < 0.05). e Heat map of gene expression of canonical
cell-type specific genes across the pre-transplanted and post-transplanted samples. f Gene ontology network of gene ontology terms
overrepresented by genes enriched in the CoMo-NSCs pre-transplantation (e). Gene ontology groups: (1) mRNA processing, splicing, export; (2)
RNA, DNA binding, repair; (3) Cell division, cell cycle; (4) Adherens junction; (5) Mismatch, double-strand break repair; (6) Ribosome biogenesis; (7)
Proteoglycans and microRNAs in cancer; (8) RNA transport, processing, splicing; (9) Organ regeneration; (10) Regulation and localization; (11) Viral
process; (12) Activity; (13) Assembly; (14) Gene expression; (15) Liver development; (16) ATP-dependent chromatin remodeling; (17) Translational
initiation. g Gene ontology network of gene ontology terms overrepresented by genes enriched in the CoMo-NSCs post-transplantation (e). Gene
ontology groups: (1) Circadian entrainment; (2) Synaptic transmission, long-term memory; (3) Signaling pathways; (4) Neuroactive ligand-receptor
interaction; (5) Glutamatergic, GABAergic synapse; (6) Neurotransmitter, glutamate, dopamine secretion; (7) Membrane potential, ion
transmembrane transport; (8) Morphine, nicotine addiction; (9) Locomotory behavior; (10) Action potential, excitatory postsynaptic potential; (11)
Calcium ion-regulated exocytosis of neurotransmitter; (12) Ion transmembrane transport, channel activity; (13) Response to amphetamine; (14)
Cardiac conduction; (15) Sensory perception of pain
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CoMo-NSCs derived from ESI-017 hESCs were
engrafted into athymic adult rat lumbar spinal cords,
and lumbar spinal cord tissue was dissected for RNA
purification and sequencing 2 and 6 months after
transplantation. RNA sequencing reads were assigned
their species of origin using our bioinformatics pipe-
line, and human cell-derived transcripts were analyzed
for differential gene expression and using principal
component analysis (Fig. 6b–d).
This analysis revealed a large-scale shift in the tran-
scriptome of the transplanted cells after 2 months
in vivo and a further change in the RNA profile at 6
months post-grafting. At 2 and 6months, approximately
5% of the total sequencing reads were derived from hu-
man cells, suggesting a remarkable degree of
xeno-engraftment. In vitro cultured CoMo-NSCs
expressed high levels of cell division genes and RNA
processing factors, while 2-month engrafted
CoMo-NSCs expressed axon guidance molecules, and
6-month CoMo-NSC progeny expressed higher levels of
enzymes involved in metabolic processes (Fig. 6e–g,
Additional file 7, Additional file 8). The 2- and 6-month
CoMo-NSCs grafted cells both shared expression of syn-
aptic vesicle and ion transport genes (Fig. 6e).
Following transplantation, NSCs are expected to gen-
erate a variety of neural cell types. We found that tran-
scripts encoding NSC marker genes (such as Sox2 and
Cxcr4) were less abundant at 2 months following en-
graftment and further reduced at 6 months (Fig. 6e).
Concomitantly, we observed an upregulation in neuronal
(Beta Tubulin class III, neuron-specific enolase, and
MAP2) and astrocyte (GFAP, CD44, AQP4, S100β)
genes, and to a lesser degree upregulation of oligo-
dendrocyte factors (OLIG1, OLIG2) (Fig. 6e). Import-
antly, pluripotent markers of ESCs, which would
represent a significant safety concern, as well as
human-specific endoderm or mesoderm transcripts (in-
dicative of teratoma formation), were not detected at
any stage following CoMo-NSC engraftment.
To define the neurotransmitter identity of grafted
neurons, we further examined markers of different
neuronal types. We found evidence for expression of
genes representative of cholinergic neurons, dopa-
minergic neurons, glutamatergic neurons, GABA/gly-
cinergic inhibitory neurons, but not serotonergic
neurons (Fig. 6e). Interestingly, consistent with im-
munofluorescence staining data, a higher activity in
genes associated with neuronal synaptically mediated
inhibition was seen, including GAD67 (GAD1) and
GAD65 (GAD2). Similarly, only moderate expression
of genes related to neuronal excitation was detected,
including VGLUT1–3 (SLC17A6, SLC17A7,
SLC17A8).CoMo-NSC engraftment in spinal injury minipigs
A transplantation protocol likely to be used in a clinical
setting will employ previously well-characterized and
frozen NSCs stored in clinical cell banks. In a recently
completed ALS trial [47] and ongoing spinal trauma trial
[11], clinical grade human fetal spinal cord-derived
NSCs previously stored in liquid nitrogen (LN) were
washed and shipped in hibernation buffer at 4 °C to the
clinical site. After a viability test was performed (the cut-
off is 70% viability), the NSCs were used directly for
spinal grafting without sub-culturing. To test this likely
cell preparation scenario, CoMo-NSCs were shipped fro-
zen to our large animal facility (IAPG, Czech Republic)
from UC San Diego and stored in LN for 4 weeks. On
the day of grafting, the CoMo-NSCs were washed 3× in
hibernation buffer and then stored at 4 °C for 2–3 h
prior to being loaded into the injection device. Cells
were injected just above and just below the injury epi-
center (L3 spinal segment) in chronic spinally injured
adult minipigs (see the “Methods” section for details).
The presence of cells was studied using immunofluores-
cence after staining with human-specific (hNUMA,
HO14, hSYN, SCI121) and non-specific (NF, VGAT,
GFAP) antibodies. In all grafted animals (n = 3),
hNUMA+ cells were detected in horizontally cut sec-
tions. Individual injection core(s) were readily identified
by the presence of dense clusters of hNUMA+ cells
(Additional file 9A, B). In the same areas, a dense net-
work of human HO14+ axons was observed (Additional
file 9A-C). Staining with human-specific synaptophysin
(hSYN) antibody showed numerous hSYN puncta
throughout the grafted region, and host neurons above
and below the injury site displayed numerous hSYN ter-
minals aligned along their surface (Additional file 9E-I).
Similar as seen in spinally grafted NSCs in immunodefi-
cient rats, co-staining with VGAT and hSYN showed nu-
merous double-stained terminals apposed with host
neurons in ventral horn and in intermediate zone (Add-
itional file 9 J).
Discussion
We describe a selection method to isolate expandable
multipotent neural stem cells from pluripotent human
embryonic stem cells. Our method relied upon serial se-
lection of neuroepithelial cells based on their columnar
morphology and radial colony organization on adherent
dishes. We call the NSCs isolated using this purification
method “colony morphology neural stem cells”
(CoMo-NSCs) to distinguish them from NSCs purified
by other previously developed methods such as FACS.
The CoMo method of cell isolation offers the advantage
that it markedly simplifies the number of reagents and
steps associated with GMP production of large quan-
tities of clinical grade neural stem cells. The use of cell
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induced progeny from ES cells is not entirely novel for
research studies [24, 27], but this approach represents a
concern for clinical applications for multiple reasons in-
cluding the possibility of heterogeneous mixtures of cells
within the NSC culture, limited expandability, and un-
predictable or unstable differentiation. Moreover, it is
critical that ES-derived NSCs are not contaminated with
embryonic stem cells due to their risk of tumor and/or
teratoma formation.
Accordingly, the goal of our current study was three-
fold: First, to define the reliability of selecting NSCs by
using colony morphology criteria as defined by (i)
in vitro expandability, (ii) long-term stable expression of
NSCs markers, (iii) lack of pluripotent markers, and (iv)
ability to re-culture and expand previously frozen (i.e.,
banked) NSCs. Second, to characterize the engraftment
properties and tumorigenic potential of NSCs trans-
planted into (i) the spinal cord of naïve-immunodeficient
rat, (ii) the spinal cord of continuously immunosup-
pressed transgenic rats that develop an aggressive form
of ALS (G93A), (iii) the spinal cord of continuously im-
munosuppressed adult minipig with chronic spinal cord
injury. Third, to develop bioinformatic tools to (i) create
a reference transcriptome for human clinical grade NSCs
with desirable growth, differentiation, and safety charac-
teristics and (ii) build an algorithm for deconvoluting
RNA transcripts from xenografts based on
species-specific SNP analysis to monitor how engrafted
cells respond to their environment and detect host tissue
responses to transplanted cells. Our findings indicate
that colony morphology selection is effective for isolat-
ing NSCs of high purity, long-term stable self-renewal
characteristics, and the ability to generate neuronal and
glial progeny in the adult CNS after in vivo grafting—
without detectable tumor or teratoma formation.
Colony morphology selection is a reliable method for
human NSC isolation from pluripotent ES cells
Animal studies with embryonic and induced pluripotent
stem cells indicate there is great potential for cell re-
placement therapies [42, 43, 48–51] but the intrinsic
variability among different ES and iPS cell lines com-
bined with the risk of contaminating tumor-forming
cells has slowed clinical translation. Isolation protocols
have been developed for differentiation and purification
of NSC lines from human ESC and iPSC. In general, one
or more specific surface markers are used for positive/
negative selection of NSCs by FACS. Depending on the
developmental stage of sorted NSCs, cells can be further
expanded or used directly for in vivo transplantation.
This approach has shown that CD56 or the combination
of CD184+/CD326− antibodies is effective for enriching
neuronal precursors [51, 52], CD133, CD15 andGCTM-2 can be used to purify neurosphere-forming
NSCs [53], CD133+/CD45−/CD34− cells correspond to
NSCs [54], and CD24, CD15, and CD29 correspond to
neuroblasts and neurons from induced hESC [55]. We
have reported on a successful isolation of NSCs from in-
duced human ES or iPS lines by using CD184+/CD271−/
CD44−/CD24+ cell surface expression signature [29].
However, a limitation in applying these methods to clin-
ical applications is the need for GMP grade antibodies.
Here, we developed and validated a manual selection
protocol to isolate NSCs from pluripotent hESCs that
expanded > 15 passages and expressed typical NSC in-
cluding Nestin, SOX1, PAX6, and SOX2. Importantly,
we also verified the lack of expression of pluripotency
transcription factor NANOG in established NSCs. Un-
like SOX2, which plays a critical role in the maintenance
of both embryonic and neural stem cells, NANOG is
only expressed in undifferentiated pluripotent stem cells
(reviewed in Zhang and Cui, 2014). The lack of NANOG
expression thus confirms the absence of pluripotent
hESCs in the established NSC population [56].
In vivo engraftment profile and safety of CoMo-NSCs
Spinally engrafted CoMo-NSCs show a predictable
time-dependent differentiation and maturation in vivo.
Consistent with normal fetal development, engrafted
NSCs generated neurons during the first 2 months
in vivo. During the period from 2 to 6 months in vivo
mature neuronal marker (NeuN, hNSE, and synaptophy-
sin) expression increased along with glial markers
(GFAP, vimentin). Using electronoptical analysis, devel-
opment of synaptic contacts with the host neurons was
also noted. Interestingly, confocal co-localization analysis
of hSYN puncta with GAD65 and VGAT revealed that in-
hibitory neurons readily emerged from NSC grafts. The
VGAT+ boutons derived from grafted CoMo-NSCs were
spatially opposed to postsynaptic gephyrin (glycine
receptor-associated protein) immunoreactivity on the host
neurons. These results mirror our previous studies which
observed the development of numerous inhibitory neu-
rons from human fetal NSCs following spinal engraftment
into immunosuppressed rat models of spinal ischemia
[57] or spinal traumatic injury [58].
Analysis of the proliferation capacity and tumorigen-
esis potential of grafted cells showed dividing Ki67+ cells
in graft areas with a high density of vimentin+ glial pre-
cursors, but overall cell proliferation was infrequently
detected at 6 months post graft. Analysis of H&E-stained
sections revealed a comparable cellularity and overall
morphology of the grafts to the surrounding mature host
CNS tissue with no detectable tumor formation, sup-
porting the absence of the NANOG-positive hESC con-
taminants in CoMo-NSC population as identified by
RNA-seq. Previous studies have demonstrated an
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self-renewing oligodendrocyte progenitors being the
main dominating proliferating cell population in the in-
tact adult mouse spinal cord [59]. We recently reported
a comparable, low-level continuing proliferation of glial
precursors in the adult pig spinal cord [60]. Accordingly,
we speculate that the limited mitotic activity of grafted
CoMo-NSCs seen in our current study at 6 months is
likely associated with ongoing oligodendrocyte prolifera-
tion and myelination at the site of human NSCs grafts.
The progressive maturation of grafted CoMo-NSCs,
low-level glial-associated mitotic activity, and develop-
ment of synaptic contacts with host neurons at 6 months
post grafting is similar to the behavior of spinally grafted
human fetal NSC line NSI-566 (Neuralstem Inc., MD,
USA). This line was successfully used in 33 patients in a
phase II ALS trial with no detectable side effects indica-
tive of tumor formation after lumbar and/or cervical
NSI-566 grafts in cell densities up to 16 million cells
[47]. Similarly as used in previous human clinical ALS
[47] or current chronic spinal trauma trial [11] which
employed the NSI-566 line for spinal grafting, a com-
bined immunosuppression protocol (tacrolimus and my-
cophenolate mofetil) was used in ALS rats receiving
NPC grafts in our current study. The differentiation pro-
file of grafted cells was similar compared to immunode-
ficient rats analyzed at approximately 2 months post
grafting. These data suggest that pharmacologically in-
duced immunosuppression does not have a major effect
of on the fate and differentiation properties of grafted
NPCs.
Taken together, CoMo-NSCs represent a transplant-
able cell population with favorable safety and differenti-
ation characteristics.
Transcriptomic and bioinformatic characterization of
CoMo-NSCs
To establish a comprehensive reference index for the mo-
lecular features of CoMo-NSCs before and after engraft-
ment, we performed mRNA sequencing and developed a
bioinformatics method to identify human transcripts from
a mixed-species graft. This method accurately identified
and sorted human mRNA reads with a false positive sort-
ing rate of only 0.3% (with 1.4% ambiguous, see methods
for detail on species sorting). Gene expression was ana-
lyzed with t-distributed stochastic neighbor embedding
(t-SNE) to determine the global gene expression patterns
in the samples. Interestingly, no correlation among all
three samples analyzed (pre-transplant CoMo-NSCs, 2
months post-transplant CoMO-NSCs and 6months
post-transplant CoMo-NSCs) was seen. Analysis of a sub-
set of genes specific to each sample cell population
showed (i) a progressive loss of immature NSCs markers
(SOX1, CXR4) after grafting and (ii) the appearance ofearly and late glial and neuronal markers at 2 and 6
months post-grafting respectively. Analysis of
CNS-specific transcripts in grafted cells showed high ex-
pression of mature neuronal markers (ENO2), neuronal
inhibitory markers (GAD65, GAD67), and mature astro-
cyte markers (GFAP, AQP4, SLC1A3). Both the RNA se-
quencing data and immunofluorescence staining revealed
abundant inhibitory neurons and well developed
human-specific GFAP immunoreactivity. Importantly, in
our current study, no expression of pluripotent markers
such as NANOG or overexpression of senescence markers
such as PRODH was seen in any sample. Analysis of the
PODXL gene showed a progressive decrease within grafts
compared to pre-transplant levels. The PODXL gene
(podocalyxin-like protein) is highly expressed in pluripo-
tent cells including proliferating NSC [61]. In addition, it
was demonstrated that high PODXL expression correlates
with increasing glioma grade and is a marker of poor out-
come in patients with glioblastoma multiforme [62].
We demonstrate that RNA sequencing can be used to
monitor the behavior of xenografts at a population level,
and can serve as a sensitive tool for quantifying the ex-
pression of markers associated with unsafe growth char-
acteristics. In addition, this technology can effectively be
used to identify any alteration in post-grafting differenti-
ation or grafted cell survival caused by in vitro
expansion-induced cell(s) senescence or apoptosis [63,
64]. Accordingly, we believe that performing mRNA se-
quencing of pre-and post-transplant NSCs in conjunc-
tion with behavioral assessment of cell-grafted animals
and post-mortem histopathological analysis of
graft-targeted tissue will lead to a substantial improve-
ment in our ability to generate and effectively screen/se-
lect safe NSCs lines to be used in a clinical setting.Conclusions
We have developed a new cell morphology-based selection
protocol to generate an expandable population of multipo-
tent NSCs from human embryonic stem cells. Using pre-
and post-in vivo transplant analysis of NSCs, we demon-
strated the phenotypic and genetic stability of in vitro
long-term expanded NSCs and predictable differentiation
profiles at 2 and 6months post-spinal grafting in rats and
minipigs. No tumor formation was noted. The simplicity
and cost-effectiveness of this NSC selection protocol appear
to provide a method of choice for the generation of clinical
grade NSCs from human pluripotent (ES or iPS) cells for
use in perspective clinical cell-replacement trials.Additional files
Additional file 1: Table S1. Cell culture media and buffer composition.
(PDF 459 kb)
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and immunofluorescence staining. (PDF 26 kb)
Additional file 3: Table S3. Experimental groups. (PDF 346 kb)
Additional file 4: Morphology of cell populations during the process of
derivation of CoMo-NSCs from pluripotent hESCs. A—Representative
image of hESC colony on mouse embryonic feeder layer. B—Manually
dissociated hESCs into smaller clumps and induced to form embryoid
bodies (EBs) in non-adherent cell culture conditions. C—Morphology of
first neural rosettes observed at days 4–12 after plating of EBs. D—Manu-
ally separated neural rosettes, dissociated into smaller pieces and trans-
ferred to new poly-L-ornithine/laminin-coated cell culture dishes. Upon
adhesion, dissected clumps of rosettes began to generate new groups of
rosettes (termed “R1”). E, F—Newly enriched population of neural ro-
settes, both fully reformed (E) and partially reformed (F), with a very small
number of contaminating cells termed as “R2”. G—Independent “clone-
like populations” of NSCs visible outside of rosettes-like structures. H,
I—Manually isolated single “clone-like population” of NSCs and re-plated
into 24 wells plate. J, K, L—Established self-renewing population of clonal
morphology NSCs, further referred to as CoMo-NSCs at low density (J),
high density (K) and high magnification (L). (scale bars: A 250 μm; B, C
500 μm; D–G 250 μm; H, I 150 μm; J, K 250 μm; L 100 μm). (JPG 2540 kb)
Additional file 5: Growth curve and doubling time of CoMo-NSCs.
A—Growth curve from three independent cell lines of established CoMo-
NSCs. B—Average doubling time of 20.96 h (± 1.51) was calculated using
formula DT = t/3.3*log b/B between day 2 and day 4 (during the expo-
nential phase of cell growth). DT = doubling time, t = time in minutes, b
= number of cells at the end time point, B = number of cells at the first
time point. (JPG 247 kb)
Additional file 6: Spinally grafted clonal NSCs give rise to mature astrocyte
and oligodendrocytes in the immunodeficient rat at 6months post-grafting.
A, B, C—A high-density network of human-specific GFAP+ processes in the
areas of hNUMA+ human grafts can be seen. D, E, F—In the same areas a sub-
population of hNUMA+ grafted cells expressed a mature oligodendrocyte
marker CC1. G—Double staining with hNUMA and Ki67 antibody showed the
only occasional presence of mitotically active grafted cells. (scale bars: A
100 μm; D 80 μm; F 10 μm; G 50 μm). (JPG 4957 kb)
Additional file 7: Pre-transplantation gene ontology terms. A—Gene
ontology terms overrepresented by genes enriched in the CoMo-NSCs
pre-transplantation. (JPG 1072 kb)
Additional file 8: Post-transplantation gene ontology terms. A—Gene
ontology terms overrepresented by genes enriched in the CoMo-NSCs
post-transplantation. (JPG 902 kb)
Additional file 9: Spinally grafted CoMo-NSCs-derived neurons show a
long-term engraftment, no tumor formation and extensive axonal sprout-
ing in adult pig with previous spinal injury. A total of 20 injections of
NSCs were injected bilaterally above and below spinal injury epicenter
(L2–L3 segments) in chronic spinally injured adult minipigs. The presence
of grafted NSCs was analyzed at 3 months after cell grafting. A, B,
C—Multiple clusters of hNUMA+ grafted cells (green signal) can be iden-
tified in horizontally cut section taken from cell-grafted region. In the
same areas a high density of grafted neuron-derived axons (HO14-red
signal) can be seen. D, E, F, G, H, I—Staining with human-specific synap-
tophysin antibody (green signal) showed a high density of hSYN puncta
on the host NF+ neurons. Numerous grafted neurons-derived axons
(HO14; white) in the vicinity of medium-sized and large host neurons can
also be seen. Only few GFAP+ grafted astrocytes (colocalizing with pan-
human SCI121 immunoreactivity) were seen (E; insert). J—Triple staining
with human-specific synaptophysin antibody, VGAT (vesicular GABA trans-
porter) and NF showed numerous double hSYN/VGAT-stained puncta on
the membranes of large neurons of the host (white arrows). (scale bars: A
500 μm; B 100 μm; C 50 μm; D 20 μm; E 30 μm; F 20 μm; G 10 μm; H
10 μm; I 20 μm; J 5 μm) (JPG 8408 kb)
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